Universita' Degli Studi di Roma La Sapienza
Welcome,         Profile    Billing    Logout  
 0 Trials 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Park, Jin-Sung
NIMBLE, NCT05070858 / 2020-003272-41: A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis

Recruiting
3
235
Europe, Canada, Japan, US, RoW
Pozelimab + Cemdisiran, Cemdisiran, ALN-CC5, Placebo, Pozelimab, REGN3918
Regeneron Pharmaceuticals
Generalized Myasthenia Gravis
05/25
03/28
ADAPT oculus, NCT06558279: A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults with Ocular Myasthenia Gravis

Recruiting
3
124
US, RoW
Efgartigimod PH20 SC, Placebo PH20 SC
argenx
Myasthenia Gravis, Ocular
12/25
12/27
MIS51ON, NCT03992430 / 2018-001762-42: A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD)

Active, not recruiting
3
160
Europe, US, RoW
Eteplirsen, AVI-4658, EXONDYS 51, EXONDYS
Sarepta Therapeutics, Inc., Sarepta Therapeutics, Inc.
Muscular Dystrophy, Duchenne
10/26
10/26
Takenobu, Yohei
NIMBLE, NCT05070858 / 2020-003272-41: A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis

Recruiting
3
235
Europe, Canada, Japan, US, RoW
Pozelimab + Cemdisiran, Cemdisiran, ALN-CC5, Placebo, Pozelimab, REGN3918
Regeneron Pharmaceuticals
Generalized Myasthenia Gravis
05/25
03/28
Kang, Minsung
MyClad, NCT06463587: Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis

Recruiting
3
240
Europe, Japan, US, RoW
Placebo, Cladribine Low Dose, Cladribine High Dose
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, EMD Serono Research & Development Institute, Inc.
Generalized Myasthenia Gravis
05/28
07/30
NIMBLE, NCT05070858 / 2020-003272-41: A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis

Recruiting
3
235
Europe, Canada, Japan, US, RoW
Pozelimab + Cemdisiran, Cemdisiran, ALN-CC5, Placebo, Pozelimab, REGN3918
Regeneron Pharmaceuticals
Generalized Myasthenia Gravis
05/25
03/28

Download Options